awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3
Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3
Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
P2860
Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c7a790740790820a5853a453903ae8028162e6fe
P2860
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.